Luca Science Inc. has raised $30.3 million in an oversubscribed series B financing, enabling it to advance a mitochondria replacement therapy toward the clinic. The company is planning a phase Ib trial in myocardial infarction, in which 8 to 12 patients will receive injections of mitochondria immediately after having a heart attack.
Swanbio Therapeutics Inc. closed a $56 million series B round to take its lead gene therapy program, SBT-101, into clinical development later this year. The candidate, comprised of an adeno-associated virus type 9 vector encoding the ABCD1 peroxisomal ATP-binding cassette transporter, is in development for adrenomyeloneuropathy (AMN), an inherited disease that affects the central nervous system.
With a 2020 launch behind it, Moma Therapeutics Inc. has completed a $150 series B financing to continue refining its pipeline of therapies targeting tough-to-drug enzymes in treating solid tumors.
Sidekick Health AB stepped into a leading role in the fast-growing digital health space with the closing of a $55 million series B this week and an ever larger number of partners for its gamified app. Designed to help better manage multiple chronic conditions, the digital therapeutic engages users in video game-like activities and rewards positive changes in lifestyle choices while delivering personalized educational components.
Ashvattha Therapeutics Inc. secured $69 million in a series B financing that it said will strengthen its ability to develop hydroxyl dendrimer-based medicines and accelerate efforts to advance its candidates to the clinic.
Tubulis GmbH has added considerable momentum to its effort to build a pipeline of novel antibody-drug conjugates (ADCs) by closing a €60 million (US$63.2 million) series B round. CEO and co-founder Dominik Schumacher told BioWorld the cash would enable the Munich-based firm to generate clinical proof of concept, build a clinical pipeline and continue development of its platform technologies.
Omass Therapeutics Ltd. has raised £75.5 million (US$94.6 million) in a series B round, as it continues to advance five small-molecule programs against previously intractable membrane-bound targets to the clinic.
Ashvattha Therapeutics Inc. secured $69 million in a series B financing that it said will strengthen its ability to develop hydroxyl dendrimer-based medicines and accelerate efforts to advance its candidates to the clinic.
After securing $70 million in series B funding, Chinese biotech Medilink Therapeutics Co. Ltd. is gearing up to enter the clinic with its next-generation antibody-drug conjugates (ADCs).
After securing $70 million in series B funding, Chinese biotech Medilink Therapeutics Co. Ltd. is gearing up to enter the clinic with its next-generation antibody-drug conjugates (ADCs).
RSS
